KNSA Q2 2024 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$109M+52.0% YoY

Gross Profit

$66M60.9% margin

Operating Income

-$117,000-0.1% margin

Net Income

-$4M-3.6% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+36.0%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$5M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$542M

Total Liabilities

$107M

Stockholders' Equity

$435M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$109M	$71M	+52.0%
Gross Profit	$66M	$49M	+35.8%
Operating Income	-$117,000	-$3M	+96.3%
Net Income	-$4M	$15M	-126.1%

Revenue Segments

Product

$103M95%

Collaboration

$5M5%